Background and Aims: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Research has shown that in CLL, microRNAs can have function as oncogenes or tumor suppressors. Some studies demonstrated that the expression of microRNA-93 (miR-93) and microRNA-330 (miR-330) have been changed in several cancers, including lung, prostate, and colon cancer. We aimed to elucidate the changes in miR-93 and miR-330 expression in CLL patients in comparison with controls. Materials and Methods: In this case-control study, the expression levels of miR-93 and miR-330 was evaluated in 30 CLL patients who had referred to Omid Hospital, Isfahan, Iran, and 30 controls in peripheral blood mononuclear cells using reverse transcription quantitative PCR (RT-qPCR). Results: The expression of miR-93 and miR-330 were found to significantly increase in CLL patients compared with controls (p<0.0001).
Introduction
Chronic lymphocytic leukemia (CLL) is a monoclonal disorder characterized by a progressive accumulation of functionally incompetent lymphocytes [1] . CLL is the most frequent type of leukemia recognized in western countries, accounting for about one-third of all cases of adult leukemias [2] . The incidence of this type of leukemia is 30 percent among all blood cancers and is slightly more common in men than in women [3] . The epidemiological evidence demonstrated that 5-10 percent of CLL cases are associated with a family history [4] .
Advancing the understanding of CLL molecular genetics may have therapeutic stratification based on molecular prognosticators [5] .
MicroRNAs (miRNAs), a new class of endogenous small noncoding RNAs with [18] [19] [20] [21] [22] nucleotides, have been associated with several types of cancer [6, 7] . miRNAs mediate posttranscriptional gene regulation, leading to the degradation or translation repression of target messenger RNAs (mRNAs) by recognization of 3' untranslated region of mRNAs [8] . In cancers, miRNAs can function as regulatory molecules or as oncogenes by down-regulating tumor suppressors [9] . The miR-15a and miR- were discovered in 2002 within the 13q14.3 deleted region in CLL [10] . miRNAs have pivotal roles in cellular and molecular processes related to CLL. However, the prognostic value of miRNAs is still unknown [11] . Some studies have shown the change in expression of miR-93
and miR-330 in several cancers including lung, prostate, and colon cancer [12] [13] [14] [15] [16] [17] . Moreover, a previous study has suggested miR-93 and miR-330 as miRNAs related to major molecular genetic alterations in acute myeloid leukemia [18] . However, the molecular mechanisms of 
Materials and Methods
Totally, 60 samples including 30 patients diagnosed with CLL in the Omid Hospital 
Statistical analysis
Real-time PCR data analysis was performed using the ΔΔCT method, where CT is the cycle threshold [20] . Data were then analyzed using (Table 1) .
Moreover, it was observed that, the levels of some variables including white blood cells, lymphocyte, and platelet counts were associated with CLL and were significantly higher in the cases than in the controls. (Fig. 1) . Additionally, the results demonstrated significant growth in the expression of miR-330 in CLL patients compared with the controls (p<0.0015) (Fig. 2) .
We observed that the CLL patients were associated with higher levels of both miRNAs expression compared with the controls. Therefore, we hypothesized that this overexpression of miR-93 and miR-330 in CLL compared to the control could be studied as a potential therapeutic target to inhibit CLL progression in the future. 
Conflict of Interest
The authors declare no conflict of interest.
